Study guide
8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
Key Takeaways Explain This Topic AI
Trauma and addiction share profound neurobiological overlap, featuring HPA-axis dysregulation, hypersecretion of corticotropin-releasing factor (CRF), amygdala hyper-reactivity, and prefrontal cortex hypo-activation.
The 'Self-Medication Hypothesis' explains substance use as an adaptive-turned-maladaptive attempt to blunt intrusive re-experiencing, severe hyperarousal, and painful emotional numbing.
SAMHSA's Six Principles of Trauma-Informed Care (Safety, Trustworthiness, Peer Support, Collaboration, Empowerment, Cultural/Gender) mandate operational changes to prevent clinical re-traumatization during physical exams, toxicology testing, and searches.
Seeking Safety is the premier evidence-based, present-focused, non-exposure integrated therapy for PTSD and SUD, safe and effective in early recovery without risking trauma-induced relapse.
Prazosin is an evidence-based alpha-1 adrenergic antagonist for trauma nightmares and sleep disruption; benzodiazepines are strictly contraindicated in PTSD and SUD due to impaired fear extinction, worse recovery, and high overdose mortality.
Last updated: September 2026
8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) specializing in addictions must synthesize neurobiological, behavioral, and pharmacological evidence to deliver Trauma-Informed Care (TIC), implementing integrated, non-retraumatizing psychotherapies and safe psychopharmacological regimens for individuals presenting with Post-Traumatic Stress Disorder (PTSD) and co-occurring substance use disorders.
- 1. Neurobiology of Trauma, Stress Systems & Addiction Vulnerability
- Hypothalamic-Pituitary-Adrenal (HPA) Axis & CRF Dysregulation
Psychological trauma, particularly when experienced during early critical neurodevelopmental windows, induces lasting structural and functional neuroendocrine alterations:
Corticotropin-Releasing Factor (CRF) Hyperactivity: Traumatic stress induces persistent hypersecretion of CRF from the paraventricular nucleus of the hypothalamus and extrahypothalamic limbic structures—specifically the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST) . Elevated central CRF drives persistent autonomic arousal, anxiety, and excessive vigilance.
HPA Allostatic Shift: Chronic severe stress results in glucocorticoid receptor down-regulation or desensitization, leading to blunted or dysregulated cortisol diurnal curves. The normal negative feedback loop of cortisol is compromised, trapping the individual in a state of allostatic overload. Neurocircuitry of Co-Occurring Trauma & Addiction:
- [Trauma / Adverse Childhood Experiences]
- │
- ▼
- ┌─────────────────────────────────┴─────────────────────────────────┐
- ▼ ▼
- [Hyperactive Amygdala & BNST] [Hypoactive vmPFC & Anterior Cingulate]
- Persistent hypersecretion of CRF • Loss of top-down inhibitory control
- Severe hyperarousal, terror, nightmares • Impaired fear extinction learning
- Exaggerated acoustic startle reflex • Deficient behavioral self-regulation
- │ │
- └─────────────────────────────────┬─────────────────────────────────┘
- │
- ▼
- [Intense Internal Dysphoria & Agony]
- (Nightmares, Flashbacks, Emotional Numbness)
- │
- ▼
- ["Self-Medication Hypothesis" (Khantzian)]
Substances recruited as external chemical modulators:
- Alcohol / Sedatives ──> Blunt hyperarousal & induce sleep
- Opioids ──────────────> Extinguish emotional pain & terror
- Cannabis ─────────────> Suppress nightmares (REM blunting)
- Stimulants ───────────> Overcome emotional numbness/anhedonia
- Functional Neuroanatomy: The Tripartite Circuit
Hyperactive Amygdala: Mediates conditioned fear acquisition, threat detection, and emotional memory consolidation. In PTSD, the amygdala fires excessively and indiscriminately to non-threatening environmental cues, initiating spontaneous sympathetic nervous system cascades (tachycardia, hypertension, diaphoresis).
Hypoactive Ventromedial Prefrontal Cortex (vmPFC) & Anterior Cingulate Cortex (ACC): The vmPFC normally exerts inhibitory, "braking" control over amygdalar output and mediates fear extinction. In trauma survivors, hypoactivation of the vmPFC permits unchecked amygdalar firing, impairing the capacity to suppress traumatic fear responses.
Hippocampal Atrophy & Contextual Deficits: High, sustained levels of glucocorticoids and stress-induced excitotoxicity produce dendritic remodeling and volume reduction in the hippocampus . Because the hippocampus provides spatio-temporal contextual tagging of memories, hippocampal dysfunction prevents the brain from recognizing that trauma is in the past; traumatic memories are re-experienced as occurring in the immediate present (intrusive flashbacks).
The "Self-Medication Hypothesis" in Trauma
Formulated by Edward Khantzian, the self-medication hypothesis posits that substance use is not primarily a pursuit of euphoria, but rather a compelling, functional attempt to alleviate unbearable, disordered affective states:
Alcohol and Sedative-Hypnotics: Recruited to enhance GABAergic inhibition and suppress hyperadrenergic surges, panic, and hyperarousal.
Opioids: Possess potent anti-rage, anti-anxiety, and psychic-pain blunting effects, chemically buffering the profound emotional agony and attachment rupture of developmental trauma.
Cannabis: High concentrations of cannabinoids blunt REM sleep, temporarily suppressing trauma-related nightmares and nocturnal terrors.
Stimulants: Used to pierce through severe emotional numbing, depersonalization, and profound anhedonia.
Adverse Childhood Experiences (ACEs) Epidemiology
The landmark CDC-Kaiser Permanente Adverse Childhood Experiences (ACE) Study revealed a staggering, graded dose-response relationship between early childhood abuse, neglect, and household dysfunction and adult addiction:
An individual with an ACE score of 4 or higher is 5 times more likely to suffer from alcohol use disorder, 4 times more likely to suffer from depression, and 10 times more likely to engage in illicit drug use or injection drug use compared to someone with an ACE score of 0.
In clinical substance use treatment programs, between 60% and 85% of patients report significant histories of physical, sexual, or emotional trauma, with co-occurring PTSD diagnosed in 30% to 50% of patients.
2. SAMHSA's Six Principles of Trauma-Informed Care (TIC)
Trauma-Informed Care represents an overarching philosophical and operational paradigm shift across healthcare delivery systems, moving fundamentally from asking "What is wrong with you?" to asking "What happened to you?" and "How did you learn to survive?" SAMHSA's Six Core Principles of Trauma-Informed Care (TIC):
1. Safety ──────────────────────── Physical, psychological, and emotional safety
for patients and healthcare staff.
2. Trustworthiness & Transparency ─ Clear, transparent operations, predictable
rules, and explicit clinical boundaries.
3. Peer Support ─────────────────── Utilizing peer specialists with lived experience
to build mutual hope and recovery capital.
4. Collaboration & Mutuality ────── Leveling power differentials; shared
decision-making between clinician and patient.
5. Empowerment, Voice & Choice ──── Cultivating patient autonomy, self-advocacy,
and recognizing innate resilience.
6. Cultural, Historical & Gender ── Moving beyond cultural stereotypes, addressing
Issues historical trauma, and providing gender-responsive care.
Operational Clinical Modifications to Avoid Re-Traumatization
Traditional addiction treatment environments often inadvertently recreate dynamics of powerlessness, control, and violation characteristic of trauma. The APRN must lead operational reforms:
1. Physical Examinations and Invasive Procedures
Clinical Vulnerability: Physical examinations, pelvic exams, or being unclothed can trigger severe panic, dissociation, or flashbacks in survivors of physical and sexual abuse.
TIC Safeguards:
Always explain every component of the physical examination before touching the patient .
Obtain explicit verbal consent prior to each step ("May I listen to your lungs now?").
Allow patients to remain fully clothed as much as clinically feasible.
Ensure a chaperone is present, and inform the patient that they have the right to pause or terminate the exam at any moment.
2. Toxicology Testing
Clinical Vulnerability: Observed urine drug screening (UDS)—where staff visually observe urine passing from the urethra into a cup—is profoundly invasive, humiliating, and directly replicates sexual violation and victimization.
TIC Safeguards:
Reserve direct observation exclusively for rare, legally mandated circumstances.
Utilize alternative, respectful collection protocols: unobserved collection in single-occupancy restrooms with colored toilet water, temperature monitoring (90°F–100°F within 4 minutes), or transition to oral fluid (saliva) testing .
Never utilize toxicology results punitively (e.g., discharge from treatment or denial of psychiatric care); treat positive screens as vital clinical data indicating a need for intensified support.
3. Room Searches and Belonging Inspections in Residential Settings
Clinical Vulnerability: Unannounced room searches or ransacking belongings replicates childhood home invasions and arbitrary boundary violations.
TIC Safeguards:
Conduct searches only when clinically necessary for community safety, and always in the presence of the patient .
Explain the purpose transparently and treat personal possessions with dignity and care.
- 3. Evidence-Based Integrated Psychotherapies for PTSD and SUD
- Seeking Safety (Lisa Najavits)
Seeking Safety is the premier, empirically validated present-focused cognitive-behavioral model designed specifically for co-occurring PTSD and substance use disorders:
Present-Focused, Non-Exposure Design: Unlike traditional trauma therapies that require detailed trauma narratives and exposure to traumatic memories, Seeking Safety does not involve trauma exposure . This critical feature ensures it is exceptionally safe in early sobriety, active substance use, and acute withdrawal , completely avoiding the risk of trauma-induced substance relapse.
Core Goal: Attaining Safety: The overarching principle is helping the patient achieve safety across four domains: safety in thinking (substituting coping thoughts for self-blame), safety in emotions (emotional regulation), safety in behavior (cessation of substance use and self-harm), and safety in interpersonal relationships (leaving abusive environments).
Structure: 25 flexible, structured modules that can be delivered in individual or group formats across inpatient, residential, or outpatient settings. Seeking Safety Core Therapeutic Architecture:
- [Principle 1: Integrated Focus] ─── Addresses PTSD and SUD simultaneously in every session
- [Principle 2: Present Focus] ────── Concentrates on current coping skills; NO trauma exposure
- [Principle 3: Four Domains] ─────── Cognitive, Behavioral, Interpersonal, and Case Management
- [Principle 4: Clinical Safety] ──── Safe in early recovery, active use, and severe instability
- Exposure-Based Therapies in Addictions: CPT, PE & EMDR
Historically, exposure-based trauma therapies were strictly withheld until patients achieved 6 to 12 months of complete abstinence, based on clinical fears that confronting traumatic memories would trigger severe cravings and fatal overdose. Modern clinical trials (e.g., the Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure [COPE] trials) have overturned this dogma:
Prolonged Exposure (PE): Involves in vivo exposure to avoided, safe trauma-related cues and imaginal exposure (repeated recounting of the trauma memory). When combined concurrently with Medication for Opioid Use Disorder (MOUD) or Medication for Alcohol Use Disorder (MAUD) , PE can be initiated once baseline medical stability and emotional regulation skills are established. It produces superior reductions in PTSD symptom severity without increasing substance relapse.
Cognitive Processing Therapy (CPT): A 12-session structured manualized therapy focusing on identifying and modifying "stuck points" (distorted core beliefs regarding safety, trust, power/control, esteem, and intimacy resulting from trauma). Highly effective when integrated into outpatient addiction recovery.
Eye Movement Desensitization and Reprocessing (EMDR): Utilizes bilateral sensory stimulation (saccadic eye movements, alternating tactile taps, or auditory tones) while focusing on traumatic memories to facilitate adaptive neurobiological reprocessing. Adapted addiction protocols (e.g., Desensitization of Triggers and Urge Reprocessing [DeTUR]) specifically target substance memory networks and relapse triggers.
- 4. Pharmacotherapy for PTSD with Co-Occurring SUD
- First-Line Antidepressant Pharmacotherapy
FDA-Approved SSRIs: Sertraline (50 mg to 200 mg daily) and Paroxetine (20 mg to 50 mg daily) are the only two FDA-approved medications for PTSD.
Clinical Impact: Effective for reducing intrusive thoughts, hyperarousal, avoidance, and comorbid depressive symptoms.
Off-Label First-Line Options: Fluoxetine (20 mg to 60 mg daily) and Venlafaxine XR (75 mg to 225 mg daily) demonstrate comparable clinical efficacy in clinical trials.
Titration Mandate: Patients with PTSD and co-occurring panic frequently exhibit hypersensitivity to initial activating antidepressant side effects. The APRN should start at low doses (e.g., sertraline 25 mg daily) and titrate slowly over several weeks to achieve therapeutic doses.
Alpha-1 Adrenergic Antagonism: Prazosin for Trauma Nightmares
Mechanism: Traumatic stress induces excessive nocturnal norepinephrine outflow from the locus coeruleus, disrupting REM sleep architecture, causing distressing autonomic arousals, violent motor activity, and terrifying trauma nightmares. Prazosin is a lipid-soluble alpha-1 adrenergic receptor antagonist that crosses the blood-brain barrier to competitively block central alpha-1 receptors, dampening nocturnal sympathetic surges.
Clinical Indications: First-line off-label evidence-based pharmacotherapy for PTSD-related nightmares, nocturnal terrors, and fragmented sleep .
Dosing & Titration Schedule:
Starting Dose: 1 mg PO at bedtime (to evaluate for first-dose syncope).
Titration: Increase by 1 mg to 2 mg every 3 to 7 days based on clinical response and tolerability.
Target Therapeutic Range: Typically 6 mg to 15 mg PO at bedtime for males; 2 mg to 8 mg PO at bedtime for females. (In severe daytime hyperarousal, small daytime doses of 1 mg to 2 mg PO may be added).
Essential APRN Monitoring: Monitor resting blood pressure and pulse , specifically assessing for orthostatic hypotension , dizziness, lightheadedness, and syncope. Instruct patients to rise slowly from a seated or lying position.
The Strict Prohibition Against Benzodiazepines in PTSD & SUD
The American Psychological Association (APA), the Department of Veterans Affairs / Department of Defense (VA/DoD), and international clinical guidelines issue an unequivocal recommendation: Benzodiazepines are strictly contraindicated in the management of PTSD, and especially in co-occurring PTSD and substance use disorders. Four Clinical Pillars Precluding Benzodiazepines in PTSD + SUD:
1. Impairment of Fear Extinction Learning:
Benzodiazepines facilitate GABA-A transmission, blunting the neuroplasticity and
amygdala-prefrontal synaptic remodeling required for fear extinction during trauma therapy.
2. Paradoxical Symptom Exacerbation:
Longitudinal studies show patients on benzodiazepines exhibit worse long-term PTSD
severity, higher rates of treatment-resistant depression, and increased emotional disinhibition.
3. High Addiction & Escalation Risk:
PTSD patients rapidly develop tolerance, physical dependence, and escalating rebound anxiety
between doses, driving compulsive misuse and illicit diversion.
4. Catastrophic Overdose Lethality:
Co-ingestion of benzodiazepines with opioids (MOUD or illicit fentanyl) or alcohol
causes synergistic brainstem respiratory arrest; present in >30% of fatal opioid overdoses.
5. Integrated Trauma-Addiction Clinical Decision Algorithm Integrated Clinical Decision Algorithm for PTSD + SUD:
- [Patient Evaluated: Meets DSM-5-TR for PTSD + SUD]
- │
- ▼
- [Establish Baseline Medical Safety]
- Initiate MOUD (Buprenorphine / Methadone) OR MAUD
- Overdose education & Naloxone distribution
- Implement Trauma-Informed Care environmental safeguards
- │
- ▼
- ┌────────────────────────────┴────────────────────────────┐
- ▼ ▼
- [Early Recovery / Active Use] [Stable Remission / Established MOUD]
- (High instability, severe distress) (Good coping capacity, stabilized cravings)
- │ │
- ▼ ▼
- [Seeking Safety (Najavits)] [Exposure-Based Trauma Psychotherapy]
- Present-focused coping skills • Prolonged Exposure (PE) OR
- Safe behavioral stabilization • Cognitive Processing Therapy (CPT) OR
- NO trauma narrative exposure • EMDR Protocol for Trauma/Addiction
- │ │
- └────────────────────────────┬────────────────────────────┘
- │
- ▼
- [Targeted Pharmacotherapy Suite]
- First-Line: Sertraline or Paroxetine (Slow titration)
- Trauma Nightmares: Prazosin (Titrate 1mg -> 6-15mg qHS)
- Breakthrough Agitation: Hydroxyzine PRN
- STRICT RULE: ZERO Benzodiazepines!
Pharmacotherapy Protocol Matrix for Co-Occurring PTSD and SUD
Agent / Drug Class Target Clinical Symptoms Starting Dose Therapeutic Maintenance Dose Critical Monitoring & Clinical Cautions
Sertraline (SSRI) Intrusions, avoidance, hyperarousal, co-occurring MDD 25 mg to 50 mg daily 100 mg to 200 mg daily FDA-approved for PTSD; start low to prevent initial jitteriness/activation; monitor GI distress
Paroxetine (SSRI) Intrusions, hyperarousal, panic symptoms 10 mg to 20 mg daily 20 mg to 50 mg daily FDA-approved; more sedating; significant anticholinergic effects; higher discontinuation syndrome
Prazosin (Alpha-1 Antagonist) Trauma-related nightmares, nocturnal awakenings, hyperhidrosis 1 mg PO at bedtime 2 mg to 15 mg PO at bedtime First-line for trauma nightmares ; monitor for orthostatic hypotension, syncope, and dizziness
Benzodiazepines (Alprazolam, Clonazepam, etc.) Contraindicated DO NOT PRESCRIBE DO NOT PRESCRIBE STRICTLY CONTRAINDICATED : Blunts fear extinction, worsens PTSD recovery, high overdose mortality